TOP TEN perturbations for 1552833_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552833_at
Selected probe(set): 1552834_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552833_at (1552834_at) across 6672 perturbations tested by GENEVESTIGATOR:

CH5183284 study 1 (NCI-H716) / vehicle (DMSO) treated NCI-H716 cell sample

Relative Expression (log2-ratio):-2.7669353
Number of Samples:2 / 2
Experimental CH5183284 study 1 (NCI-H716)
Human cecum cell line NCI-H716 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated NCI-H716 cell sample
Human cecum cell line NCI-H716 treated with 0.1% DMSO for 24 hours.

colorectal cancer study 33 (carcinoma; colonic crypt) / adjacent colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-2.4841633
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colonic crypt epithelial cell sample
Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)

Relative Expression (log2-ratio):2.4687767
Number of Samples:4 / 2
Experimental rectal cancer study 2 (post; chemoradiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; no therapy)
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):-2.2150059
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

rectal cancer study 2 (post; radiotherapy) / rectal cancer study 2 (post; chemoradiotherapy)

Relative Expression (log2-ratio):-2.2059221
Number of Samples:4 / 4
Experimental rectal cancer study 2 (post; radiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after treatment with short-course neoadjuvant radiotherapy (RT; 25Gy in 5 fractions). Samples were collected after 1 week of completing the therapy. Patients were selected for neoadjuvant RT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation, and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; chemoradiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

colorectal cancer study 25 / adjacent colon tissue

Relative Expression (log2-ratio):-2.0119352
Number of Samples:94 / 17
Experimental colorectal cancer study 25
Human primary colorectal carcinoma sample.
Control adjacent colon tissue
Normal colon tissue samples adjacent to tumor from patients with colorectal cancer.

colorectal cancer study 30 / normal colorectal tissue

Relative Expression (log2-ratio):-1.934948
Number of Samples:45 / 4
Experimental colorectal cancer study 30
Formalin-fixed-paraffin-embedded (FFPE) colorectal tissue samples from patients with colorectal cancer.
Control normal colorectal tissue
Healthy, non-tumor colorectal tissue.

colorectal cancer study 33 (carcinoma; colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-1.932766
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal cancer study 4 (non-recurring) / adjacent colon tissue (non-recurring)

Relative Expression (log2-ratio):-1.9208574
Number of Samples:76 / 18
Experimental colorectal cancer study 4 (non-recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients did not develop metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (non-recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). No metastatic recurrence during follow-up.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)

Relative Expression (log2-ratio):1.8829718
Number of Samples:2 / 25
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma.